Results 211 to 220 of about 99,790 (252)

Inhibition of HMGA2 Leads to Reduced Cell Proliferation and Increased Apoptosis in Human Embryonal Carcinoma Cell Lines

Andrology, EarlyView.
ABSTRACT Background The most prevalent solid tumors in young men are testicular germ cell tumors (TGCTs), and embryonal carcinoma is the most common subtype among non‐seminomatous germ cell tumors (NSGCTs). Despite the excellent cure rates of cisplatin‐based chemotherapy, resistance develops in 15%–30% of patients with metastatic cancer, which results ...
Marco De Martino, Matteo Lampitto, Alfredo Fusco, Marco Barchi, Francesco Esposito, Paolo Chieffi   +5 more
wiley   +1 more source

ST6GAL1 promotes cancer stem-like cell-associated paclitaxel resistance through the EGFR-mTOR-SOX2/BMI1 axis in non-small cell lung cancer. [PDF]

Cancer Drug Resist
Yang Y, Liang B, Hong W, Lee SH, Tang D, Xie S, Qin C, Shen L, Sun Z, Yan X, Li H, Wang X, Hu X, Ye T, Zhang W, Xu W.   +15 more
europepmc   +1 more source

A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics

Andrology, EarlyView.
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis, Lisa Schneider, Felix Bremmer, Daniel Nettersheim   +3 more
wiley   +1 more source

Targeting RPRD1B overcomes chemoresistance in gastric cancer by suppressing the TOPBP1-mediated DNA damage repair pathway. [PDF]

Cell Oncol (Dordr)
Sheng J, Li J, Cao C, Liu X, He C, Fei M, Wu B, Li X, Hu C, Liu S, Lv Y.   +10 more
europepmc   +1 more source

Proteomic Profiling of Bone Marrow Aspirates from Patients with Methotrexate- and Vincristine-Resistant B-Cell Acute Lymphoblastic Leukemia: A Retrospective Analysis. [PDF]

Pharmaceuticals (Basel)
Flores-Palma EJ, Gonzalez-Tolentino DL, Encarnación-Guevara S, Gil J, Alonso-Bastida R, Martínez-Batallar AG, Saavedra-Herrera MV, Ibarra-Sierra E, Gómez-Gómez Y, Illades-Aguiar B, Garibay-Cerdenares OL, Leyva-Vázquez MA.   +11 more
europepmc   +1 more source

A phase IIa study of the anti‐PD‐L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL‐T trial

British Journal of Haematology, EarlyView.
The AVAIL‐T study, the first evaluation of programmed death ligand 1 (PD‐L1) blockade in relapsed/refractory peripheral T‐cell lymphomas (PTCL), demonstrated limited single agent activity with durable responses seen in a minority. Circulating tumour DNA revealed distinct mutational dynamics and mass cytometry identified perturbed T‐cell subsets ...
Matthew J. Ahearne, Matthew A. Timmins, Charlotte Gaskell, Aimee Jackson, Clare Morland, Sonia Fox, Louise Hopkins, Nadia Nawaz, Susann Lehmann, Marc Wadsley, Caroline Cowley, Jacqueline Shaw, Naeem Khan, Nagesh Kalakonda, Christopher Trethewey, Ram Malladi, Paul Fields, Dima El Sharkawi, Michael Quinn, Nimish Shah, Andrew Davies, Kim Linton, Pam McKay, Rod Johnson, Simon D. Wagner, David Lewis, Graham P. Collins, Christopher P. Fox, Kate Cwynarski   +28 more
wiley   +1 more source

Mechanisms and advances of drug resistance in colorectal cancer: A systematic overview of multi-layered regulatory networks. [PDF]

Transl Oncol
Qiu S, Li S, Chen Y, Ma X, Fu H, Zhao B.
europepmc   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source

Targeting drug efflux in pancreatic cancer: what the PANTAX trial teaches us about resisting resistance. [PDF]

Ann Pancreat Cancer
Abdel-Razeq N, Mukhopadhyay D, Babiker H.   +2 more
europepmc   +1 more source